PUBLISHER: The Business Research Company | PRODUCT CODE: 1760583
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760583
Isovaleric acidemia (IVA) treatment involves managing a rare inherited metabolic disorder caused by a deficiency in the enzyme isovaleryl-CoA dehydrogenase, resulting in the buildup of isovaleric acid in the body. The goal of treatment is to decrease the accumulation of toxic substances and prevent metabolic crises.
The primary types of IVA treatment are classical isovaleric acidemia, moderate isovaleric acidemia, and non-classical isovaleric acidemia. Classical IVA is a severe metabolic disorder caused by the deficiency of isovaleryl-CoA dehydrogenase, which plays a crucial role in metabolizing the amino acid leucine. Treatments for IVA include dietary management, enzyme replacement therapy, gene therapy, and pharmacological interventions. These treatments are administered either orally or through injections and are provided in various settings, such as hospitals, clinics, and home care environments.
The isovaleric acidemia (IVA) treatment market research report is one of a series of new reports from The Business Research Company that provides isovaleric acidemia (IVA) treatment market statistics, including the isovaleric acidemia (IVA) treatment industry global market size, regional shares, competitors with the isovaleric acidemia (IVA) treatment market share, detailed isovaleric acidemia (IVA) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the isovaleric acidemia (IVA) treatment industry. This isovaleric acidemia (IVA) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The isovaleric acidemia (IVA) treatment market size has grown strongly in recent years. It will grow from $0.60 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period of isovaleric acidemia (IVA) treatment can be attributed to awareness of rare metabolic disorders, expansion of newborn screening programs aiding early diagnosis, growing government funding for orphan diseases, focus on enzyme replacement therapies, and rising demand for early diagnosis and genetic counseling. These efforts have improved IVA detection and management, leading to better patient outcomes.
The isovaleric acidemia (IVA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Looking to the forecast period, the growth of IVA treatment is expected to be driven by the increasing adoption of gene therapy approaches, rising investments in rare disease research, a growing pipeline of novel treatment options, and more collaborations between biotech firms and research institutions. There's also a rising emphasis on personalized medicine, particularly for metabolic disorders such as IVA. Major trends that are likely to shape the future of IVA treatment include advancements in genetic testing technologies, innovative drug delivery systems for metabolic therapies, improvements in enzyme replacement formulations, the development of targeted gene editing tools, and progress in newborn screening methodologies. These trends have the potential to improve the effectiveness of treatments and make them more accessible, offering hope for better management and outcomes for patients with IVA.
The increasing prevalence of metabolic disorders is expected to propel the growth of the isovaleric acidemia (IVA) treatment market. Metabolic disorders, such as diabetes mellitus, hypothyroidism, hyperthyroidism, and isovaleric acidemia (IVA), disrupt normal metabolic processes and affect how the body converts food into energy. The prevalence of these disorders is rising, primarily due to lifestyle-related factors such as poor diet and physical inactivity, leading to conditions such as obesity and insulin resistance. Isovaleric acidemia treatment addresses the buildup of toxic substances in the body, helping to restore normal metabolic function and preventing complications such as neurological damage. For example, according to the American Diabetes Association, approximately 25.5 million people in the U.S. were diagnosed with diabetes in 2022, accounting for 7.6% of the population. This increasing prevalence of metabolic disorders is driving the growth of the IVA treatment market.
The growing awareness of rare genetic disorders is also expected to propel the growth of the IVA treatment market. Rare genetic disorders, caused by mutations in genes, often affect a small number of individuals but are becoming more visible due to advancements in diagnostic technologies and genetic screening programs. These improvements allow for earlier and more accurate detection, leading to better management of these conditions. Isovaleric acidemia treatment specifically addresses this rare genetic disorder by offering specialized dietary regimens, amino acid supplementation, and sometimes medications to reduce the buildup of toxic metabolites and prevent metabolic crises. In February 2023, the World Health Organization reported that birth abnormalities, including conditions such as heart defects and neural tube defects, contribute to thousands of deaths annually. Additionally, a study conducted at Rady Children's Hospital revealed that 41% of infant deaths were due to single-locus (Mendelian) genetic diseases. These findings underscore the importance of raising awareness and improving diagnosis for rare genetic disorders, further fueling the growth of the IVA treatment market.
The rising adoption of personalized medicine is also driving the growth of the IVA treatment market. Personalized medicine, which tailors treatment based on individual characteristics such as genetics, lifestyle, and environment, is increasingly prevalent due to advancements in genetic testing and biomarker research. In the case of isovaleric acidemia, personalized medicine involves utilizing genetic insights to customize dietary and pharmacological interventions based on an individual's metabolic profile. This approach enhances treatment outcomes and reduces complications. For instance, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022, according to the Personalized Medicine Coalition. As personalized healthcare continues to evolve, the growth of the IVA treatment market is expected to accelerate, driven by the need for tailored therapies that improve patient outcomes.
Major players in the isovaleric acidemia (iva) treatment market are Nestle Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.
North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isovaleric acidemia (IVA) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the isovaleric acidemia (IVA) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The isovaleric acidemia (IVA) treatment market consists of revenues earned by entities by providing services such as newborn screening programs, monitoring, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The isovaleric acidemia (IVA) treatment market includes sales of anticatabolic agents, L-carnitine supplements, and amino acid supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Isovaleric Acidemia (IVA) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on isovaleric acidemia (iva) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for isovaleric acidemia (iva) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The isovaleric acidemia (iva) treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.